Tobacco dependence and withdrawal: Science base, challenges and opportunities for pharmacotherapy

Pharmacology and Therapeutics

Volumn 123, Issue 1, 2009, Pages 1-16

  Henningfield, Jack E ^a   Shiffman, Saul ^b   Ferguson, Stuart G ^b   Gritz, Ellen R ^c  

^a PINNEY ASSOCIATES   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

brain; brain imaging; bupropion; drug; efficacy; epidemiology; gum; inhaler; lozenge; mechanism; nasal; nicotine; nicotine replacement therapy; patch; pharmacotherapy; policy; receptors; tobacco; treatment; varenicline; withdrawal

Indexed keywords

AMFEBUTAMONE; CANNABINOID RECEPTOR ANTAGONIST; CLONIDINE; COMMIT; CYTISINE; NALTREXONE; NICOTINE; NICOTINE GUM; NICOTINE PATCH; NICOTINE VACCINE; NICOTINIC RECEPTOR; NORTRIPTYLINE; PLACEBO; RIMONABANT; UNCLASSIFIED DRUG; VARENICLINE;

CLINICAL TRIAL; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG SAFETY; DRUG TARGETING; HEALTH CARE POLICY; HUMAN; LOW DRUG DOSE; MATERNAL SMOKING; NEUROBIOLOGY; NICOTINE REPLACEMENT THERAPY; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; SMOKING CESSATION; SUBSTANCE ABUSE; SUSTAINED RELEASE PREPARATION; TOBACCO DEPENDENCE; TREATMENT RESPONSE; WITHDRAWAL SYNDROME;

ANIMALS; BENZAZEPINES; BUPROPION; CLINICAL TRIALS AS TOPIC; HUMANS; NICOTINE; QUINOXALINES; RECEPTORS, NICOTINIC; SUBSTANCE WITHDRAWAL SYNDROME; TOBACCO USE CESSATION; TOBACCO USE DISORDER; TREATMENT OUTCOME;

EID: 65849445884     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2009.03.011     Document Type: Review

References (191)

1. Abrams D.B., Niaura R., Brown R.A., Emmons K.M., Goldstein M.G., and Monti P.M. The Tobacco Dependence Treatment Handbook: a Guide to Best Practices (2003), The Guilford Press, New York
2. Alberg A.J., Patnaik J.L., May J.W., Hoffman S.C., Gitchell J., Comstock G.W., et al. Nicotine replacement therapy use among a cohort of smokers. J. Addict. Dis. 24 (2005) 101-113
3. American Legacy Foundation. Youth tobacco cessation: Results from the 2000 National Youth Tobacco survey (2003), American Legacy Foundation, Washington, DC
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. third ed. (1980), American Psychiatric Association, Washington, DC
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (Third Edition - Revised) (1987), American Psychiatric Association, Washington, DC
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. fourth ed. (1994), American Psychiatric Association, Washington, DC
7. American Psychiatric Association. Diagnostic and statistical manual - IVTR (2000), American Psychiatric Association, Washington, D.C.
8. Asher M.K., Martin R.A., Rohsenow D.J., MacKinnon S.V., Traficante R., and Monti P.M. Perceived barriers to quitting smoking among alcohol dependent patients in treatment. J Subst Abuse Treat 24 (2003) 169-174
9. Balster R.L., and Bigelow G.E. Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend 70 (2003) S13-S40
10. Barnoya J., and Glantz S. Association of the California tobacco control program with declines in lung cancer incidence. Cancer Causes Control 15 (2004) 689-695
11. Benhammou K., Lee M., Strook M., Sullivan B., Logel J., Raschen K., et al. [(3)H]Nicotine binding in peripheral blood cells of smokers is correlated with the number of cigarettes smoked per day. Neuropharmacology 39 (2000) 2818-2829
12. Bennett D., Burton A.W., Fishman S., Fortner B., McCarberg B., Miaskowski C., et al. Consensus panel recommendations for the assessment and management of breakthrough pain part 1: assessment. Pharmacol Ther 30 (2005) 296-301
13. Bennett D., Burton A.W., Fishman S., Fortner B., McCarberg B., Miaskowski C., et al. Consensus panel recommendations for the assessment and management of breakthrough pain part 2: management. Pharmacol Ther 30 (2005) 354-361
14. Benowitz N.L. Cardiovascular toxicity of nicotine: pharmacokinetic and pharmacodynamic considerations. In: Benowitz N.L. (Ed). Nicotine safety and toxicity (1998), Oxford University Press, New York 19-27
15. Benowitz N., and Dempsey D. Pharmacotherapy for smoking cessation during pregnancy. Nicotine Tob Res 6 Suppl 2 (2004) S189-S202
16. Benwell M.E., Balfour D.J., and Anderson J.M. Evidence that tobacco smoking increases the density of (-)-[3H]nicotine binding sites in human brain. J Neurochem 50 (1988) 1243-1247
17. Bonnie, R. J., Stratton, K., & Wallace, R. B. (Eds.) (2007). Ending the tobacco problem: A blue print for the nation. Institute of Medicine of the National Academies. Washington DC: The National Academies Press.
18. Boyle P., Gray N., Henningfield J.E., Seffrin J., and Zatonski W. Tobacco and Public Health: Science and Policy (2004), Oxford University Press, Oxford, UK
19. Breese C.R., Marks M.J., Logel J., Adams C.E., Sullivan B., Collins A.C., et al. Effect of smoking history on [3H]nicotine binding in human postmortem brain. J Pharmacol Exp Ther 282 (1997) 7-13
20. Brown S., Inskip H., and Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 177 (2000) 212-217
21. Buchhalter A.R., Fant R.V., and Henningfield J.E. Nicotine. In: Sibley D.R., Hanin I., Kuhar M., and Skolnick P. (Eds). Handbook of contemporary neuropharmacology (2007), John Wiley & Sons, Inc 535-566
22. Buchhalter A.R., Fant R.V., and Henningfield J.E. Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status. Drugs 68 (2008) 1067-1088
23. Buisson B., and Bertrand D. Chronic exposure to nicotine upregulates the human (alpha)4(beta)2 nicotinic acetylcholine receptor function. J Neurosci 21 (2001) 1819-1829
24. Centers for Disease Control. Nicotine addiction: a report of the Surgeon General. The Health Consequences of Smoking (1988) 241-375
25. Centers for Disease Control and Prevention. Ten great public health achievements - United States, 1900-1999. MMWR: Morb Mort Wkly Rep 48 (1999) 241-243
26. Centers for Disease Control and Prevention. Annual smoking-attributable mortality, years of potential life lost, and economic costs - United States, 1995-1999. MMWR: Morb Mort Wkly Rep 51 (2002) 300-303
27. Cheeta S., Tucci S., and File S.E. Antagonism of the anxiolytic effect of nicotine in the dorsal raphe nucleus by dihydro-beta-erythroidine. Pharmacol Biochem Behav 70 (2001) 491-496
28. Clayton R.R., Ries M.K., and Abrams D.B. Introduction to tobacco, nicotine, and youth: the tobacco etiology research network. Drug Alcohol Depend 59 Suppl 1 (2000) S1-S4
29. Cnattingius S. The epidemiology of smoking during pregnancy: smoking prevalence, maternal characteristics, and pregnancy outcomes. Nicotine Tob Res 6 Suppl 2 (2004) S125-S140
30. Colby S.M., Tiffany S.T., Shiffman S., and Niaura R.S. Are adolescent smokers dependent on nicotine? A review of the evidence. Drug Alcohol Depend 59 Suppl 1 (2000) S83-S95
31. Colby S.M., Tiffany S.T., Shiffman S., and Niaura R.S. Measuring nicotine dependence among youth: a review of available approaches and instruments. Drug Alcohol Depend 59 Suppl 1 (2000) S23-S39
32. Cone E.J., Fant R.V., and Henningfield J.E. Nicotine and tobacco. In: Mozayani A., and Raymon L.P. (Eds). Handbook of drug interactions: a clinical and forensic guide (2004), Humana Press, Totowa, New Jersey 463-492
33. Cornuz J., Pinget C., Gilbert A., and Paccaud F. Cost-effectiveness analysis of the first-line therapies for nicotine dependence. Eur J Clin Pharmacol 59 (2003) 201-206
34. Curkendall S.M., Mo J., Glasser D.B., Rose S.M., and Jones J.K. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J Clin Psychiatry 65 (2004) 715-720
35. Dalack G.W., and Meador-Woodruff J.H. Acute feasibility and safety of a smoking reduction strategy for smokers with schizophrenia. Nicotine Tob Res 1 (1999) 53-57
36. Dasgupta P., Kinkade R., Joshi B., Decook C., Haura E., and Chellappan S. Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and surviving. Proc Natl Acad Sci U S A 103 (2006) 6332-6337
37. DeNoble V.J., and Mele P.C. Intravenous nicotine self-administration in rats: effects of mecamylamine, hexamethonium and naloxone. Psychopharmacology (Berlin) 184 (2006) 266-272
38. Ershoff D., Ashford T.H., and Goldenberg R. Helping pregnant women quit smoking: an overview. Nicotine Tob Res 6 Suppl 2 (2004) S101-S105
39. Etter J.F. Cytisine for smoking cessation: a literature review and a meta-analysis. Arch Int Med 166 (2006) 1553-1559
40. Fagerstrom K.O. Can reduced smoking be a way for smokers not interested in quitting to actually quit?. Respiration 72 (2005) 216-220
41. Fant R.V., Buchhalter A.R., and Henningfield J.E. Pharmacotherapy for tobacco dependence. In: Henningfield J.E., London E.D., and Pogun S. (Eds). Nicotine Psychopharmacology (2009), Springer-Verlag, Berlin Heidelberg 488-510
42. Ferguson S.G., Shiffman S., and Gwaltney C.J. Does reducing withdrawal severity mediate nicotine patch efficacy? A randomized clinical trial. J Consult Clin Psychol 74 (2006) 1153-1161
43. Fiore M.C., Bailey W.C., Cohen S.J., Dorfman S.F., Goldstein M.G., Gritz E.R., et al. Treating tobacco use and dependence. Clinical practice guideline (2000), U.S. Department of Health and Human Services. Public Health Service, Rockville, MD
44. Fiore M.C., Bailey W.C., Cohen S.J., Dorfman S.F., Goldstein M.G., Gritz E.R., et al. Treating tobacco use and dependence. Clinical practice guideline (2008), U.S. Department of Health and Human Services. Public Health Service, Rockville, MD
45. Fiore M.C., Shi F.Y., Heishman S., and Henningfield J.E. The effect of smoking and smoking withdrawal on flight performance: a 1994 update to Centers for Disease Control and Prevention National Center for Chronic Disease Prevention and Health Promotion Office on Smoking and Health (Rep. No. 9386129) (1994)
46. Fiscella K., and Franks P. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. JAMA: J Am Med Assoc 275 (1996) 1247-1251
47. Flay B.R., and Clayton R.R. Contexts and adolescent tobacco use trajectories. Addiction 98 (2003) iii-iv
48. Flores C.M., Davila-Garcia M.I., Ulrich Y.M., and Kellar K.J. Differential regulation of neuronal nicotinic receptor binding sites following chronic nicotine administration. J Neurochem 69 (1997) 2216-2219
49. Food and Drug Administration. Regulations restricting the sale and distribution of cigarettes and smokeless tobacco products to protect children and adolescents; proposed rule analysis regarding FDA's jurisdiction over nicotine-containing cigarettes and smokeless tobacco products; notice. Fed Regist 60 (1995) 41314-41792
50. Food and Drug Administration. Regulations restricting the sale and distribution of cigarettes and smokeless tobacco to protect children and adolescents; final rule. Fed Regist 61 (1996) 44396-45318
51. Food and Drug Administration. The smoking cessation aids varenicline (marketed as Chantix) and bupropion (marketed as Zyban and generics): suicidal ideation and behavior. FDA Saf Newslett 2 1 (2009) 1-4
52. George T.P., and O'Malley S.S. Current pharmacological treatments for nicotine dependence. Trends Pharmacol Sci 25 (2004) 42-48
53. Gilbert A.R., Pinget C., Bovet P., Cornuz J., Shamlaye C., and Paccaud F. The cost effectiveness of pharmacological smoking cessation therapies in developing countries: a case study in the Seychelles. Tob Control 13 (2004) 190-195
54. Giovino G.A., Henningfield J.E., Tomar S.L., Escobedo L.G., and Slade J. Epidemiology of tobacco use and dependence. Epidemiol Rev 17 (1995) 48-65
55. Gray N. Global tobacco control policy. In: Boyle P., Gray N., Henningfield J.E., Seffrin J., and Zatonski W. (Eds). Tobacco and public health: Science and policy (2004), Oxford University Press, Oxford, UK 659-668
56. Gritz E.R., Dresler C., and Sarna L. Smoking, the missing drug interaction in clinical trials: ignoring the obvious. Cancer Epidemiol Biomark Prev 14 (2005) 2287-2293
57. Gritz E.R., Fingeret M.C., Vidrine D.J., Lazev A.B., Mehta N.V., and Reece G.P. Successes and failures of the teachable moment: smoking cessation in cancer patients. Cancer 106 (2006) 17-27
58. Gritz E.R., Fiore M.C., and Henningfield J.E. Smoking and cancer. In: Murphy G.P., Lawrence W., and Lenhard R.E. (Eds). American Cancer Society textbook of clinical oncology. 2nd ed. (1995), American Cancer Society, Atlanta 146-163
59. Gritz E.R., Lam C.Y., Vidrine D.J., and Fingeret M.C. Cancer prevention: tobacco dependence and its treatment. In: Devita V., Lawrence T., and Rosenberg S. (Eds). Cancer: principles and practice of Oncology. 8th ed (2008)
60. Gritz E.R., Vidrine D.J., and Fingeret M.C. Smoking cessation a critical component of medical management in chronic disease populations. Am J Prev Med 33 (2007) S414-S422
61. Harris G. F.D.A. requiring suicide studies in drug trials (2008). http://www.nytimes.com/2008/01/24/washington/24fda.html Retrieved January 22, 2009, from: http://www.nytimes.com/2008/01/24/washington/24fda.html
62. Haviland L., Thornton A.H., Carothers S., Hund L., Allen J.A., Kastens B., et al. Giving infants a great start: launching a national smoking cessation program for pregnant women. Nicotine Tob Res 6 Suppl 2 (2004) S181-S188
63. Heishman S.J., Taylor R.C., and Henningfield J.E. Nicotine and smoking: A review of effects on human performance. Experimental & Clinical Psychopharmacology 2 4 (1994) 345-395
64. Henningfield J.E., and Benowitz N.L. Pharmacology and nicotine addiction. In: Boyle P., Gray N., Henningfield J.E., Seffrin J., and Zatonski W. (Eds). Tobacco and public health: science and policy (2004), Oxford University Press, Oxford 129-147
65. Henningfield J.E., Benowitz N.L., Ahijevych K., Garrett B.E., Connolly G.N., and Wayne G.F. Does menthol enhance the addictiveness of cigarettes? An agenda for research. Nicotine Tob Res 5 (2003) 9-11
66. Henningfield J.E., Benowitz N.L., Connolly G.N., Davis R.M., Gray N., Myers M.L., et al. Reducing tobacco addiction through tobacco product regulation. Tob Control 13 (2004) 132-135
67. Henningfield J.E., Fant R.V., Buchhalter A.R., and Stitzer M.L. Pharmacotherapy for nicotine dependence. CA: Can J Clin 55 (2005) 281-299
68. Henningfield J.E., Michaelides T., and Sussman S. Developing treatment for tobacco addicted youth - Issues and challenges. J Child Adolesc Subst Abuse 9 (2000) 5-26
69. Henningfield J.E., Moolchan E.T., and Zeller M. Regulatory strategies to reduce tobacco addiction in youth. Tob Control 12 Suppl 1 (2003) I14-I24
70. Henningfield J.E., and Slade J. Tobacco-dependence medications: public health and regulatory issues. Food Drug Law J 53 (1998) 75-114 suppl
71. Hughes J.R. Reduced smoking: an introduction and review of the evidence. Addiction 95 Suppl 1 (2000) S3-S7
72. Hughes J.R. Effects of abstinence from tobacco: etiology, animal models, epidemiology, and significance: a subjective review. Nicotine Tob Res 9 (2007) 329-339
73. Hughes J.R. Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob Res 9 (2007) 315-327
74. Hughes J.R. Measurement of the effects of abstinence from tobacco: a qualitative review. Psychol Addict Behav 21 (2007) 127-137
75. Hughes J.R., and Carpenter M.J. Does smoking reduction increase future cessation and decrease disease risk? A qualitative review. Nicotine Tob Res 8 (2006) 739-749
76. Hughes J.R., and Kalman D. Do smokers with alcohol problems have more difficulty quitting?. Drug Alcohol Depend 82 (2006) 91-102
77. Hughes J.R., Shiffman S., Callas P., and Zhang J. A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tob Control 12 (2003) 21-27
78. Hurt R.D. Pharmacotherapy for alcoholic smokers. Alcoholism: Clin Exp Res 26 (2002) 1939-1941
79. Hurt R.D., Offord K.P., Croghan I.T., Gomez-Dahl L., Kottke T.E., Morse R.M., et al. Mortality following inpatient addictions treatment. Role of tobacco use in a community-based cohort. JAMA: J Am Med Assoc 275 (1996) 1097-1103
80. International Agency for Research on Cancer. Smokeless tobacco and some tobacco-specific N-Nitrosamines, IARC monographs on the evaluation of carcinogenic risks to humans Vol. 89 (2007), World Health Organization, Lyon, France
81. Jacobson P.D., Lantz P.M., Warner K.E., Wasserman J., Pollack H.A., and Ahlstrom A.K. Combating teen smoking (2001), The University of Michigan Press, Ann Arbor
82. Jarvik M.E., and Henningfield J.E. Pharmacological treatment of tobacco dependence. Pharmacol Biochem Behav 30 (1988) 279-294
83. Jorenby D.E., Leischow S.J., Nides M.A., Rennard S.I., Johnston J.A., Hughes A.R., et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. New Engl J Med 340 (1999) 685-691
84. Joseph A.M., Norman S.M., Ferry L.H., Prochazka A.V., Westman E.C., Steele B.G., et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. New Engl J Med 335 (1996) 1792-1798
85. Joukamaa M., Heliovaara M., Knekt P., Aromaa A., Raitasalo R., and Lehtinen V. Mental disorders and cause-specific mortality. Br J Psychiatry 179 (2001) 498-502
86. Kimmel S.E., Berlin J.A., Miles C., Jaskowiak J., Carson J.L., and Strom B.L. Risk of acute first myocardial infarction and use of nicotine patches in a general population. J Am Coll Cardiol 37 (2001) 1297-1302
87. Koob G.F., and Le Moal M. Plasticity of reward neurocircuitry and the 'dark side' of drug addiction. Nat Neurosci 8 (2005) 1442-1444
88. Koob G.F., and Le Moal M. Neurobiology of addiction (2006), Elsevier, Amsterdam, NL
89. Koop C.E. Tobacco addiction: Accomplishments and challenges in science, health, and policy. Nicotine & Tobacco Research 5 (2003) 613-619
90. Koop E.C. Tobacco: the public health disaster of the twentieth century. In: Boyle P., Gray N., Henningfield J.E., Seffrin J., and Zatonski W. (Eds). Tobacco and public health: science and policy (2004), Oxford University Press, Oxford, UK v-xvii
91. Krishnan-Sarin S., Meandzija B., and O'Malley S. Naltrexone and nicotine patch smoking cessation: a preliminary study. Nicotine Tob Res 5 (2003) 851-857
92. Lamb R.J., Preston K.L., Schindler C.W., Meisch R.A., Davis F., Katz J.L., et al. The reinforcing and subjective effects of morphine in post-addicts: a dose-response study. J Pharmacol Exp Ther 259 (1991) 1165-1173
93. Lanza S.T., Donny E.C., Collins L.M., and Balster R.L. Analyzing the acquisition of drug self-administration using growth curve models. Drug Alcohol Depend 75 (2004) 11-21
94. Lasser K., Boyd J.W., Woolhandler S., Himmelstein D.U., McCormick D., and Bor D.H. Smoking and mental illness: A population-based prevalence study. JAMA: J Am Med Assoc 284 (2000) 2606-2610
95. Leischow S.J. JAMA: J Am Med Assoc 301 (2009) 1058-1060
96. Lemon S.C., Friedmann P.D., and Stein M.D. The impact of smoking cessation on drug abuse treatment outcome. Addict Behav 28 (2003) 1323-1331
97. Leonard S., and Bertrand D. Neuronal nicotinic receptors: from structure to function. Nicotine Tob Res 3 (2001) 203-223
98. Leonard S., and Bertrand D. Neuronal nicotinic receptors: from structure to function. Nicotine Tob Res 3 (2001) 203-223
99. Lerman C., LeSage M.G., Perkins K.A., O'Malley S.S., Siegel S.J., Benowitz N.L., et al. Translational research in medication development for nicotine dependence. Nat. Rev Drug Discov 6 (2007) 746-762
100. Lewin L. Phantastica: a classic survey on the use and abuse of mind-altering plants (1998), Park Street Press, Rochester, VT
101. Lynch B.S., and Bonnie R.J. Toward a youth-centered prevention policy. In: Lynch B.S., and Bonnie R.J. (Eds). Growing up tobacco free: preventing nicotine addiction in children and youths (1994), National Academy Press, Washington, DC 3-25
102. Malson J.L., Sims K., Murty R., and Pickworth W.B. Comparison of the nicotine content of tobacco used in bidis and conventional cigarettes. Tob Control 10 (2001) 181-183
103. Mansvelder H.D., Keath J.R., and McGehee D.S. Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron 33 (2002) 905-919
104. Mansvelder H.D., and McGehee D.S. Long-term potentiation of excitatory inputs to brain reward areas by nicotine. Neuron 27 (2000) 349-357
105. Markou A., and Paterson N.E. The nicotinic antagonist methyllycaconitine has differential effects on nicotine self-administration and nicotine withdrawal in the rat. Nicotine Tob Res 3 (2001) 361-373
106. Marks M.J., Pauly J.R., Gross S.D., Deneris E.S., Hermans-Borgmeyer I., Heinemann S.F., et al. Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment. J Neurosci 12 (1992) 2765-2784
107. Mayhew K.P., Flay B.R., and Mott J.A. Stages in the development of adolescent smoking. Drug Alcohol Depend 59 Suppl 1 (2000) S61-S81
108. McRobbie H., and Hajek P. Nicotine replacement therapy in patients with cardiovascular disease: guidelines for health professionals. Addiction 96 (2001) 1547-1551
109. Miettinen O.S. The need for randomization in the study of intended effects. Stat Med 2 (1983) 267-271
110. Mihalak K.B., Carroll F.I., and Luetje C.W. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol 70 (2006) 801-805
111. Mokdad A.H., Mark J.S., Stroup D.F., and Gerberding J.L. Actual causes of death in the United States, 2000. JAMA: J Am Med Assoc 291 (2004) 1238-1245
112. Montoya I.D., Herbeck D.M., Svikis D.S., and Pincus H.A. Identification and treatment of patients with nicotine problems in routine clinical psychiatry practice. Am J Addict 14 (2005) 441-454
113. Moolchan E.T., Ernst M., and Henningfield J.E. A review of tobacco smoking in adolescents: treatment implications. J Am Acad Child Adolesc Psych 39 (2000) 682-693
114. Niaura R., Sayette M., Shiffman S., Glover E.D., Nides M., Shelanski M., et al. Comparative efficacy of rapid-release nicotine gum versus nicotine polacrilex gum in relieving smoking cue-provoked craving. Addiction 100 (2005) 1720-1730
115. Nisell M., Nomikos G.G., and Svensson T.H. Nicotine dependence, midbrain dopamine systems and psychiatric disorders. Pharm Toxicol 76 (1995) 157-162
116. Orleans T., Melvin C., Marx J., Maibach E., and Vose K.K. National action plan to reduce smoking during pregnancy: the National Partnership to Help Pregnant Smokers Quit. Nicotine Tob Res 6 Suppl 2 (2004) S269-S277
117. Oster G., Huse D.M., Delea T.E., and Colditz G.A. Cost-effectiveness of nicotine gum as an adjunct to physician's advice against cigarette smoking. JAMA: J Am Med Assoc 256 (1986) 1315-1318
118. Perry D.C., Davila-Garcia M.I., Stockmeier C.A., and Kellar K.J. Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. J Pharmacol Exp Ther 289 (1999) 1545-1552
119. Picciotto M.R., Zoli M., Rimondini R., Lena C., Marubio L.M., Pich E.M., et al. Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 391 (1998) 173-177
120. Picciotto M.R., Zoli M., Rimondini R., Lena C., Marubio L.M., Pich E.M., et al. Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 391 (1998) 173-177
121. Pierce J.P., and Gilpin E.A. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA: J Am Med Assoc 288 (2002) 1260-1264
122. Pierce J.P., Gilpin E., and Farkas A.J. Nicotine patch use in the general population: results from the 1993 California Tobacco Survey. J Natl Cancer Inst 87 (1995) 87-93
123. Rabinoff M., Caskey N., Rissling A., and Park C. Pharmacological and chemical effects of cigarette additives. Am J Public Health 97 (2007) 1981-1991
124. Report Buyer (2007). Pipeline insight: substance dependence - part I: nicotine. Retrieved February 9, 2009, from: http://www.reportbuyer.com/pharma_healthcare/company_reports_pharmaceuti cal_/pipeline_insight_substance_dependence_part_i_nicotine.html
125. Robbins J., Aragaki A.K., Kooperberg C., Watts N., Wactawski-Wende J., Jackson R.D., et al. Factors associated with 5-year risk of hip fracture in postmenopausal women. JAMA: J Am Med Assoc 298 (2007) 2389-2398
126. Robert Wood Johnson Foundation. Tobacco Control Policy (2007), John Wiley & Sons, Inc, San Francisco
127. Rose J.E. Nicotine and nonnicotine factors in cigarette addiction. Psychopharmacology (Berlin) 184 (2006) 274-285
128. Rose J.E., and Hickman C.S. Citric acid aerosol as a potential smoking cessation aid. Chest 92 (1987) 1005-1008
129. Rossetti Z.L., Melis F., Carboni S., Diana M., and Gessa G.L. Alcohol withdrawal in rats is associated with a marked fall in extraneuronal dopamine. Alcoholism: Clin Exp Res 16 (1992) 529-532
130. Rowell P.P., and Wonnacott S. Evidence for functional activity of up-regulated nicotine binding sites in rat striatal synaptosomes. J Neurochem 55 (1990) 2105-2110
131. Royal College of Physicians. Nicotine addiction in Britain: A Report of the Tobacco Advisory Group of the Royal College of Physicians (2000), Royal College of Physicians of London, London, UK
132. Royal College of Physicians. Harm reduction in nicotine addiction: Helping people who can't quit (2007), Royal College of Physicians of London, London, UK
133. Sanderson E.M., Drasdo A.L., McCrea K., and Wonnacott S. Upregulation of nicotinic receptors following continuous infusion of nicotine is brain-region-specific. Brain Res 617 (1993) 349-352
134. Sarnyai Z., Shaham Y., and Heinrichs S.C. The role of corticotropin-releasing factor in drug addiction. Pharmacol Rev 53 (2001) 209-243
135. Schilstrom B., Nomikos G.G., Nisell M., Hertel P., and Svensson T.H. N-methyl-D-aspartate receptor antagonism in the ventral tegmental area diminishes the systemic nicotine-induced dopamine release in the nucleus accumbens. Neuroscience 82 (1998) 781-789
136. Schilstrom B., Svensson H.M., Svensson T.H., and Nomikos G.G. Nicotine and food induced dopamine release in the nucleus accumbens of the rat: putative role of alpha7 nicotinic receptors in the ventral tegmental area. Neuroscience 85 (1998) 1005-1009
137. Schuster C.R., and Henningfield J. Conference on abuse liability assessment of CNS drugs. Drug Alcohol Depend 70 (2003) S1-S4
138. Shadel W.G., Shiffman S., Niaura R., Nichter M., and Abrams D.B. Current models of nicotine dependence: what is known and what is needed to advance understanding of tobacco etiology among youth. Drug Alcohol Depend 59 Suppl 1 (2000) S9-S22
139. Sharples C.G., Kaiser S., Soliakov L., Marks M.J., Collins A.C., Washburn M., et al. UB-165: a novel nicotinic agonist with subtype selectivity implicates the alpha4beta2* subtype in the modulation of dopamine release from rat striatal synaptosomes. J Neurosci 20 (2000) 2783-2791
140. Shiffman S., Brockwell S.E., Pillitteri J.L., and Gitchell J.G. Smoking cessation attempts and use of smoking cessation treatments in the United States. Am J Prev Med 34 (2008) 102-111
141. Shiffman S., Brockwell S.E., Pillitteri J.L., and Gitchell J.G. Individual differences in adoption of treatment for smoking cessation: demographic and smoking history characteristics. Drug Alcohol Depend 93 (2008) 121-131
142. Shiffman S., Di Marino M.E., and Sweeney C.T. Characteristics of selectors of nicotine replacement therapy. Tob Control 14 (2005) 346-355
143. Shiffman S., Engberg J., Paty J.A., Perz W., Gnys M., Kassel J.D., et al. A day at a time: Predicting smoking lapse from daily urge. J Abnorm Psychology 106 (1997) 104-116
144. Shiffman S., and Ferguson S.G. Nicotine patch therapy prior to quitting: A meta-analysis. Addiction 103 (2008) 557-563
145. Shiffman S., Gwaltney C.J., Balabanis M.H., Liu K.S., Paty J.A., Kassel J.D., et al. Immediate antecedents of cigarette smoking: an analysis from ecological momentary assessment. J Abnorm Psychology 111 (2002) 531-545
146. Shiffman S., Hughes J.R., Di Marino M.E., and Sweeney C.T. Patterns of over-the-counter nicotine gum use: persistent use and concurrent smoking. Addiction 98 (2003) 1747-1753
147. Shiffman S., Hughes J.R., Pillitteri J.L., and Burton S.L. Persistent use of nicotine replacement therapy: an analysis of actual purchase patterns in a population based sample. Tob Control 12 (2003) 310-316
148. Shiffman S., Mason K.M., and Henningfield J.E. Tobacco dependence treatments: review and prospectus. Annu. Rev Public Health 19 (1998) 335-358
149. Silagy C., Lancaster T., Stead L., Mant D., and Fowler G. Nicotine replacement therapy for smoking cessation (2004). Cochrane Database Syst Rev (2004) CD000146
150. Simon J.A., Duncan C., Carmody T.P., and Hudes E.S. Bupropion for smoking cessation: a randomized trial. Arch Int Med 164 (2004) 1797-1803
151. Slade J. Adolescent nicotine use and dependence. Adolesc Med 4 (1993) 305-320
152. Slade J. Adolescent nicotine use and dependence. Adolescent Medicine 4 2 (1993) 305-320
153. Slade J., Bickel W.K., Crowley T.J., Ferrence R., Henningfield J.E., Houston T.P., et al. The role of managing nicotine in controlling the tobacco epidemic. In: Ferrence R., Slade J., Room R., and Pope M. (Eds). Nicotine and public health (2000), American Public Health Association, Washington, D.C. 483-501
154. Slade J., and Henningfield J.E. Tobacco product regulation: context and issues. Food Drug Law J 53 (1998) 43-74 suppl
155. Song F., Raftery J., Aveyard P., Hyde C., Barton P., and Woolacott N. Cost-effectiveness of pharmacological interventions for smoking cessation: a literature review and a decision analytic analysis. Med Decis Mak 22 (2002) S26-S37
156. Spillane J., and McAllister W.B. Keeping the lid on: a century of drug regulation and control. Drug Alcohol Depend 70 (2003) S5-12
157. Stead L.F., and Lancaster T. Interventions to reduce harm from continued tobacco use. Cochrane Database Syst Rev (2007) CD005231
158. Stead L., Perera R., Bullen C., Mant D., and Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev (2008) CD000146
159. Sussman S., Lichtman K., Ritt A., and Pallonen U.E. Effects of thirty-four adolescent tobacco use cessation and prevention trials on regular users of tobacco products. Subst Use Misuse 34 (1999) 1469-1503
160. Sweeney C.T., Fant R.V., Fagerstrom K.O., McGovern J.F., and Henningfield J.E. Combination nicotine replacement therapy for smoking cessation: rationale, efficacy and tolerability. CNS Drugs 15 (2001) 453-467
161. Thomson I.S.I. Physicians' desk reference (2008). http://www.pdr.net/login/Login.aspx Retrieved February 9, 2009, from: http://www.pdr.net/login/Login.aspx
162. Tomar S.L., Connolly G.N., Wilkenfeld J., and Henningfield J.E. Declining smoking in Sweden: is Swedish Match getting the credit for Swedish tobacco control's efforts?. Tob Control 12 (2003) 368-371
163. U.S. Department of Health and Human Services (1989). Reducing the health consequences of smoking: 25 years of progress: a report of the Surgeon General Rockville, Maryland: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.
164. U.S. Department of Health and Human Services (1990). The health benefits of smoking cessation - Report of the Surgeon General. (Rep. No. (CDC) 90-8416). U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.
165. U.S. Department of Health and Human Services (1994). Preventing tobacco use among young people: a report of the Surgeon General. Atlanta: U.S.Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.
166. U.S. Department of Health and Human Services (2000). Reducing tobacco use: a report of the Surgeon General. Atlanta, Georgia: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.
167. U.S. Department of Health and Human Services. Women and smoking: a report of the Surgeon General (2001), U.S. Government Printing Office, Washington, DC
168. U.S. Department of Health and Human Services. Health consequences of smoking - A report of the Surgeon General (2004)
169. U.S.Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Health Promotion and Education, & Office on Smoking and Health. The health consequences of smoking: nicotine addiction. A report of the Surgeon General (1988), U.S. Government Printing Office, Rockville, MD
170. Watkins S.S., Koob G.F., and Markou A. Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob Res 2 (2000) 19-37
171. Wayne G.F., Connolly G.N., and Henningfield J.E. Assessing internal tobacco industry knowledge of the neurobiology of tobacco dependence. Nicotine Tob Res 6 (2004) 927-940
172. Wayne G.F., Connolly G.N., and Henningfield J.E. Brand differences of free-base nicotine delivery in cigarette smoke: the view of the tobacco industry documents. Tob Control 15 (2006) 189-198
173. Wayne G.F., Connolly G.N., Henningfield J.E., and Farone W.A. Tobacco industry research and efforts to manipulate smoke particle size: implications for product regulation. Nicotine Tob Res 10 (2008) 613-625
174. Weiss F., Markou A., Lorang M.T., and Koob G.F. Basal extracellular dopamine levels in the nucleus accumbens are decreased during cocaine withdrawal after unlimited-access self-administration. Brain Res 593 (1992) 314-318
175. West R., DiMarino M.E., Gitchell J., and McNeill A. Impact of UK policy
176. West R., and Zhou X. Is nicotine replacement therapy for smoking cessation effective in the "real world"? Findings from a prospective multinational cohort study. Thorax 62 (2007) 998-1002
177. Williams J.M., and Ziedonis D. Addressing tobacco among individuals with a mental illness or an addiction. Addict Behav 29 (2004) 1067-1083
178. Windsor R., Oncken C., Henningfield J., Hartmann K., and Edwards N. Behavioral and pharmacological treatment methods for pregnant smokers: issues for clinical practice. J Am Med Women's Assoc 55 (2000) 304-310
179. Woolacott N.F., Jones L., Forbes C.A., Mather L.C., Sowden A.J., Song F.J., et al. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technol Assess 6 (2002) 1-245
180. World Bank. Curbing the epidemic: governments and the economics of tobacco control (1999), World Bank, Washington, DC
181. World Health Organization. The ICD-10 classification of mental behavioural disorders (1992), World Health Organization, Geneva
182. World Health Organization. Advancing knowledge on regulating tobacco products (monograph) (2001), World Health Organization, Geneva, Switzerland
183. World Health Organization. Policy recommendations for smoking cessation and treatment of tobacco dependence (2003), World Health Organization, Geneva
184. World Health Organization. The millennium development goals and tobacco control (2004), World Health Organization, Geneva, Switzerland
185. World Health Organization. Advisory note waterpipe tobacco smoking: health effects, research needs and recommended actions by regulators (2006). http://www.who.int/tobacco/global_interaction/tobreg/Waterpipe Retrieved February 9, 2009, from: www.who.int/tobacco/global_interaction/tobreg/Waterpipe%20recomm endation_Final.pdf
186. World Health Organization. The scientific basis of tobacco product regulation (2007), World Health Organization, Geneva, Switzerland
187. World Health Organization. Framework convention on tobacco control (2008). http://www.who.int/fctc/en/ Retrieved February 10, 2009 from: http://www.who.int/fctc/en/
188. World Health Organization. WHO report on the global tobacco epidemic, 2008: The MPOWER package (2008). http://www.who.int/tobacco/mpower/en/ Retrieved February 11, 2009, from: http://www.who.int/tobacco/mpower/en/
189. Ziedonis, D.M. (2007). Tobacco dependence and psychiatric illness. Unpublished manuscript.
190. Ziedonis D.M., Kosten T.R., Glazer W.M., and Frances R.J. Nicotine dependence and schizophrenia. Hospit Commun Psychiatry 45 (1994) 204-206
191. Ziedonis D.M., and Williams J.M. Management of smoking in people with psychiatric disorders. Curr Opin Psychiatry 16 (2003) 305-315